 Connection
Breelyn Wilky to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Breelyn Wilky has written about Programmed Cell Death 1 Receptor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.400 |
|
|
|
-
Wilky BA, Julian KA, Maleddu A, Mailhot AC, Cartwright CR, Gao D, Moreno Tellez C, Kemp LE, Therrien NR, Chaudhry SS, Rytlewski JD, Brockman QR, Davila E, Elias AD. A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas. Clin Cancer Res. 2025 Jul 15; 31(14):2945-2956.
Score: 0.203
-
Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J, Delepine C, Chand D, Avagyan M, Wu W, Johnson B, Grossman JE, O'Day S, Trent JC, Jones RL, Tsimberidou AM. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas. J Clin Oncol. 2025 Apr 10; 43(11):1358-1368.
Score: 0.197
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|